Oral ANAVEX 2-73: Additional Phase IIa data

Data from 32 patients with mild to moderate AD in Part A of an open-label, crossover, Australian Phase IIa trial showed that ANAVEX 2-73 was well tolerated. Additionally, ANAVEX-273 improved MMSE score by 1.5 points from baseline to week 5. ANAVEX-273 also improved Cogstate Identification Task and Cogstate One Back Task scores from baseline to week 5 (p<0.05 and p<0.001, respectively). Interim data from 14 patients in the Part B portion of the trial showed that ANAVEX 2-73 improved ADCS-ADL score by 3.21 points from baseline of Part B to week 12, with 11 of 14 patients showing improvement. Anavex said the trial was not designed to capture statistical significance of cognitive endpoints. ...